

## INDEX

---

*Note: Page numbers followed by f indicate figures and t indicate tables.  
CP-1 and CP-2 indicate unpaginated color plates.*

- β and γ secretase inhibitors, 147-149
- β-blockers, 168
- ε2-4 alleles (APOE), 80-81, 153-154
  
- Aβ (amyloid-beta) peptides, 101-102, 103f, 104, 105f, 147-149
- Aβ-derived diffusible ligands (ADDLs), 104-105
- Abilify, 164t
- Accuracy (diagnostic), 82-83, 84t-85t, 86-87
- Acetyl-L-carnitine, 147-149
- AChEs (acetylcholinesterases), 119, 120t, 121, 129, 130f, 131, 133-134
- AChs (acetylcholines), 106-108, 117t, 118-119
- Acidosis or alkalosis (serum), 54-55
- Acute subdural hematomas, 46t
- AD (Alzheimer's disease) and other dementias (diagnoses and management). *See also under individual topics.*
  - AD-specific topics, 73-152
    - natural history, 89-99
    - pathophysiology and neuropathology, 101-111
    - risk factors, genetics, biomarkers, and diagnostic accuracy, 73-87
    - therapies (current and emerging), 113-152
  - clinical trials and studies. *See* Clinical trials and studies.
  - dementing disorders topics, 11-72
    - definitions, 11-13
    - epidemiology, 15-19
    - evaluation processes and procedures, 21-43
    - non-AD disorders, 45-72
  - drugs and drug therapies. *See* Drugs and drug therapies.
  - patient management topics, 153-182
    - agitation and behavioral symptoms management, 153-168
    - family education and support, 169-182
  - resources and references for, 183-232
    - clinician and family resources, 183-191
    - references, 192-232
- ADAPT (Alzheimer's Disease Anti-Inflammatory Prevention Trial), iv, 144-145, 151t-152t
- ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive Subscale), 121, 122t-125t, 126, 128f, 129, 130f, 132f, 134-135
- ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) Inventory, 132f
- ADCS-ADLsev (Alzheimer's Disease Cooperative Study-Activities of Daily Living, modified for severe dementia) Inventory, 140f
- Addison's disease, 46t
- ADDLs (Aβ-derived diffusible ligands), 104-105
- ADEAR Center, 187, 189
- Administration on Aging, 184
- Adrenoleukodystrophy, 48t
- Advanced AD (Alzheimer's disease), 98-99
- Age (risk factor), 73

- Agitation and behavioral symptoms management, 153-168  
 assessments and evaluations for, 159, 160f, 161, 162t, 163, 164t-165t, 166-168  
 decision trees for, 160f  
 nonpharmacologic management strategies, 161, 162t  
 overviews of, 159, 160f, 161  
 pharmacologic management strategies, 163, 164t-165t, 166-168.  
*See also* Drugs and drug therapies.
- of eating difficulties, 158-159  
 of hallucinations and delusions, 155-156  
 overviews of, 153-154  
 of physical and verbal agitation, 154-155  
 psycho-behavioral metaphors and, 154  
 of sleep disruption, 158  
 of wandering and pacing, 156-157
- Alcoholism, 46t
- Algorithms (evaluation processes and procedures), 23, 24f
- Alpha-tocopherol (vitamin E), 115t, 117t, 141-144, 142t
- ALS (amyotrophic lateral sclerosis), 48t
- Alzheimer's Association, 183
- Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT), iv, 144-145, 151t-152t
- Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), 121, 122t-125t, 126, 128f, 129, 130f, 132f, 134-135
- Alzheimer's Disease Center (Boston University), 183-184
- Alzheimer's Disease Cooperative Study-Activities of Daily Living, modified for severe dementia (ADCS-ADLsev) Inventory, 140f
- Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Inventory, 132f
- Alzheimer's Disease Education and Referral Center, 183
- Alzheimer's Disease International, 183
- Alzheimer's Disease Neuroimaging Initiative (National Institute on Aging), 86-87, 186
- Alzheimer's Foundation of America, 183
- Alzheimer's Research Forum, 183
- American Academy of Neurology, 126
- American Association of Homes and Services for the Aging, 184
- American Bar Association (Commission on Law and Aging), 184
- American Health Assistance Foundation, 184
- American Health Care Association, 184
- American Society on Aging, 184
- Amnesic MCI (mild cognitive impairment), 94-96
- Amyloid-beta (A $\beta$ ) peptides, 101-102, 103f, 104, 105f, 147-149
- Amyotrophic lateral sclerosis (ALS), 48t
- AN-1792, 147-149
- Ancillary diagnostic studies, 37-43  
 brain biopsies, 43  
 for CJD, 41-42  
 CT, 38-40, 42-43  
 EEGs, 41-42  
 FDG-PET, 43  
 functional imaging studies and fMRI, 42-43, CP-1, CP-2  
 laboratory blood tests, 40-41  
 lumbar punctures and CSF analyses, 40-41
- MRI, 38-43  
 neuropsychologic evaluations, 39  
 overviews of, 37-38  
 PET, 42-43  
 polysomnography, 41-42  
 structural imaging studies, 39-40  
 T1 and T2 scans, 40  
 VDRL tests, 38, 41
- Animal models, 111
- Anoxia, 48t
- Anticholinergic agents, 54t
- Anticonvulsants, 54t, 164t-165t, 168
- Antidepressants, 52t-54t, 164t-165t, 166-167
- Antihistamines, 54t
- Antihypertensive agents, 54t
- Anti-inflammatory agents, 116, 117t, 144-145
- Anti-luteinizing hormone therapies, 117t
- Antioxidants, 116, 117t, 139, 141-144
- Anxiolytics, 164t-165t, 167
- APOE (apolipoprotein E), 80-81, 111, 153-154
- APP  $\beta$  and  $\gamma$  secretase inhibitors, 102, 103f, 104, 105f, 147-149
- Aricept, 120t, 127, 128f, 129
- Aripiprazole, 164t
- Arteritis, 48t
- Assessments and evaluations, 21-43, 159-168  
 for agitation and behavioral symptoms management, 159, 160f, 161, 162t, 163, 164t-165t, 166-168  
 ancillary diagnostic studies, 37-43  
 measurement instruments for. *See* Measurement instruments.  
 mental status assessments, 30-33, 34f, 35, 36t, 37  
 processes and procedures for, 21-43. *See also* Evaluation processes and procedures.
- Assisted living options, 178, 179f, 180-181
- Atypical neuroleptics, 164t-165t, 166
- Autoimmune disorders, 47t
- Bacterial meningitis and encephalitis, 46t
- Basophilic inclusion body disease, 67-69
- Behavioral symptoms and agitation management, 153-168  
 assessments and evaluations for, 159, 160f, 161, 162t, 163, 164t-165t, 166-168  
 decision trees for, 160f  
 nonpharmacologic management strategies, 161, 162t  
 overviews of, 159, 160f, 161  
 pharmacologic management strategies, 163, 164t-165t, 166-168.  
*See also* Drugs and drug therapies.
- of eating difficulties, 158-159  
 of hallucinations and delusions, 155-156  
 overviews of, 153-154  
 of physical and verbal agitation, 154-155  
 psycho-behavioral metaphors and, 154  
 of sleep disruption, 158  
 of wandering and pacing, 156-157
- Benzodiazepines, 164t-165t, 167

- Benzoquinone, 143-144
- Bibliography. *See* Resources and references.
- Binswanger's disease, 48t
- Biomarkers, 81
- Blood tests (laboratory), 40-41
- Boston University (Alzheimer's Disease Center), 183-184
- Bovine spongiform encephalopathy (BSE), 70
- Brain abscesses, 46t
- Brain biopsies, 43
- Brief mental evaluations, 31-33
- BSE (bovine spongiform encephalopathy), 70
- Bupropion, 52t-53t
- Busiprone, 164t-165t, 167
- Butylcholinesterase, 119, 120t, 121
- CAA (cerebral amyloid angiopathy), 60-61
- Cache County Memory and Aging Study, iv
- CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), 60-61
- Calcium antagonists, 147-149
- Carbamate inhibitors, 121
- Carbamazepine, 164t-165t, 168
- Carbon monoxide intoxication, 48t
- Carcinomas, 46t
- Cardiac arrest, 48t
- Cardiac failure, 48t
- Caregiver support, 169-182. *See also* Family education and support.
- Caregiving careers and caregiver stress, 170-171
- Carnitine (acetyl-L), 147-149
- Case-control (retrospective) trials and studies, 15
- Causes, 46t-48t
  - irreversible, 48t
  - potentially reversible, 46t-48t
- Celecoxib, 151t
- Celexa, 52t-53t, 165t
- Centers for Medicare & Medical Services, 185
- Central nervous system (CNS) vasculitis, 47t
- CERAD (Consortium to Establish a Registry for Alzheimer's Disease), 110-111
- Cerebral amyloid angiopathy (CAA), 60-61
- Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 60-61
- Cerebral embolisms, 48t
- Cerebrolysin, 147-149
- ChATs (choline acetyltransferases), 106-108, 107f
- ChEIs (cholinesterase inhibitors), 114, 114f, 116, 117t, 118-119, 126-127, 131, 133-135, 136t, 139, 159
- Chelation therapy, 148-149
- Chlorpromazine, 163, 164t-165t, 166
- Choline acetyltransferases (ChATs), 106-108, 107f
- Cholinergic agonists, 118-119
- Cholinergic enhancements, 116, 117t, 118-119, 120t, 121, 122t-125t, 126-127, 128f, 129, 130f, 131, 132f, 133-135, 136t. *See also under individual drugs and drug types.*
- ACh receptor blockers, 118-119
- ACHes, 119, 120t, 121, 129, 130f, 131, 133-134
- Aricept, 120t, 127, 128f, 129
- butylcholinesterase, 119, 120t, 121
- carbamate inhibitors, 121
- ChEIs, 118-119, 126-127, 131, 133-135, 136t
- cholinergic agonists, 118-119
- clinical trials and studies of, 121, 122t-125t, 126
- Cognex, 126
- donepezil, 120t, 122t-123t, 127, 128f, 129
- Exelon, 120t, 129, 130f, 131
- galantamine, 120t, 124t, 131, 132f, 133
- Hup A, 133-134
- memantine, 61, 117t, 124t, 135, 137-139, 140f
- metrifonate, 133-134
- nonspecific cholinesterases, 119, 120t, 121
- overviews of, 116, 117t, 118
- Reminyl, 120t, 131, 132f, 133
- rivastigmine, 120t, 122t-123t, 129, 130f, 131
- scopolamine, 118
- side effects of, 134
- tacrine (tetrahydroaminoacridine), 121, 122t, 126-127
- Cholinergic synapses, 107f
- Cholinesterase inhibitors (ChEIs), 114, 114f, 116, 117t, 118-119, 126-127, 131, 133-135, 136t, 139, 159
- Chronic subdural hematomas, 46t
- CIBIC-Plus (Clinician's Interview-Based Impression of Change with caregiver input), 121, 122t-125t, 126, 128f, 129, 130f, 134-135, 140f
- Citalopram, 52t-53t, 165t
- CJD (Creutzfeldt-Jakob disease), 41-42, 48t, 69-70
- Clinical courses vs treatment consequences, 115f
- Clinical heterogeneity, 91-92
- Clinical trials and studies. *See also under individual topics.*
  - case-control (retrospective), 15
  - of cholinergic enhancements, 121, 122t-125t, 126
  - cohort (prospective), 15
  - epidemiologic, 15, 16f, 17-18, 19f
  - incidence, 17
  - measurement instruments for. *See also under individual instruments.*
    - ADAS-Cog, 121, 122t-125t, 126, 128f, 129, 130f, 132f, 134-135
    - ADCS-ADL Inventory, 132f
    - ADCS-ADLsev Inventory, 140f
    - CIBIC-Plus, 121, 122t-125t, 126, 128f, 129, 130f, 134-135, 140f
    - Cornell Scale for Depression in Dementia, 36f
    - Demential Mood Assessment, 36f
    - Functional Assessment Questionnaire, 27, 28f-29f
    - Geriatric Depression Scale, 35, 36t, 37
    - Hamilton Depression Scale, 36f
    - MMSE, 11-12, 31-33, 34f, 35-36, 90-91, 91f, 126, 127, 128f, 129, 131, 133, 151t, 172, 175-176, 179f
    - NPI, 132f
    - PDS, 130f
    - QoL Scale, 128f, 129
    - SIB, 140f

- TICSm questionnaire, 150t-152t
- named. *See also under individual trials and studies.*
- ADAPT, iv, 144-145, 151t-152t
- Cache County Memory and Aging Study, iv
- DATATOP, 150t-152t
- GEMS, 150t-152t
- Heart Protection Study, 150t-152t
- HERS, 150t-152t
- MIRAGE Study, iv
- NIH Clinical Trials (National Library of Medicine), 184
- PREADVISE, 150t-152t
- PROSPER, 151t-152t
- REVEAL Study, iv, 81
- WHI-PERT, 151t-152t
- population-based, 17-18, 19f
- prevalence, 15, 16f, 17
- Clinic-based estimates, 19f
- Clinician and family resources, 183-191
- Clinician's Interview-Based Impression of Change with caregiver input (CIBIC-Plus), 121, 122t-125t, 126, 128f, 129, 130f, 134-135, 140f
- Clioquinol, 148-149
- Clonidine, 146-149
- Clozapine, 164t-165t, 166
- CNS (central nervous system) vasculitis, 47t
- Coenzyme Q (CoQ), 117t, 143-144
- Cognex, 126
- Cohort (prospective) trials and studies, 15
- Commission on Law and Aging (American Bar Association), 184
- Common symptoms, 23t
- Communication (physician-patient and physician-caregiver), 171-173
- Conjugated equine estrogen, 150t-152t
- Consortium to Establish a Registry for Alzheimer's Disease (CERAD), 110-111
- CoQ (coenzyme Q), 117t, 143-144
- Cornell Scale for Depression in Dementia, 36f
- Corticosteroids, 54t
- Corticotropin-releasing factor enhancers, 117t
- COX and COX-2 (cyclooxygenase and cyclooxygenase-2) inhibitors, 144-145
- Crainocerebral injuries, 46t, 48t
- Creutzfeldt-Jakob disease (CJD), 41-42
- Cryptococcal meningitis, 46t
- CSF (cerebrospinal fluid) analyses, 40-41
- CT (computed tomography), 38-40, 42-43
- Current and emerging therapies, 113-152. *See also Therapies (current and emerging).*
- Current symptoms and patient histories, 25-26
- Cushing's disease, 46t
- Cyclooxygenase and cyclooxygenase-2 (COX and COX-2) inhibitors, 144-145
- DATATOP (Deprenyl and Tocopherol Antioxidative Therapy for Parkinson's Disease), 150t-152t
- Decision trees (assessments and evaluations), 160f
- Definitions, 11-13
  - of dementias
  - as diagnoses, 12-13
  - as a syndrome, 11
  - as syndrome of persistent cognitive impairment in adults, 13
  - as unsuccessful aging shorthand, 11-12
- DSM-IV and, 12-13
- future perspectives of, 13
- overviews of, 11
- Degenerative diseases, 48t
- Dehydroepiandrosterone (DHEA), 146
- Delusions and hallucinations, 155-156
- Dementia pugilistica, 48t
- Demential Mood Assessment, 36f
- Dementing disorders topics, 11-72. *See also under individual topics.*
  - definitions, 11-13
  - epidemiology, 15-19
  - evaluation processes and procedures, 21-43
  - non-AD disorders, 45-72
- Depakote, 164t
- Deprenyl and Tocopherol Antioxidative Therapy for Parkinson's Disease (DATATOP), 150t-152t
- Depression, 35-51, 47t, 50t
  - non-AD (Alzheimer's disease) disorders and, 47t, 49, 50t, 51
  - screenings for, 35, 36, 37
- Desipramine, 52t-53t
- DHEA (dehydroepiandrosterone), 146
- Diagnoses and management concepts. *See also under individual topics.*
  - AD-specific topics, 73-152
    - natural history, 89-99
    - pathophysiology and neuropathology, 101-111
    - risk factors, genetics, biomarkers, and diagnostic accuracy, 73-87
    - therapies (current and emerging), 113-152
  - clinical trials and studies. *See Clinical trials and studies.*
  - dementing disorders topics, 11-72
    - definitions, 11-13
    - epidemiology, 15-19
    - evaluation processes and procedures, 21-43
    - non-AD disorders, 45-72
  - drugs and drug therapies. *See Drugs and drug therapies.*
  - patient management topics, 153-182
    - agitation and behavioral symptom management, 153-168
    - family education and support, 169-182
  - resources and references for, 183-232
    - clinician and family resources, 183-191
    - references, 192-232
- Diagnostic accuracy, 82-83, 84t-85t, 86-87
- Diagnostic and Statistical Manual of Mental Disorders*, fourth edition (DSM-IV), 12-13
- Diagnostic studies (ancillary), 37-43. *See also Ancillary diagnostic studies.*
- Diet, 47t, 158-159
  - eating difficulties and, 158-159
  - nutritional disorders and, 47t
- Diffuse Lewy body diseases (DLBDs), 48t, 62, 64, 65t
- Diffuse plaques (DPs), 104-105
- Diffusible ligands, 104-105

Disseminated lupus erythematosus, 47t  
 Divalproex sodium, 164t  
 DLBDs (diffuse Lewy body diseases), 48t, 62, 64, 65t  
 Donepezil, 120t, 122t-123t, 127, 128f, 129, 139  
 Dopamine agonists, 54t  
 Doxepin, 52t-53t, 164t-165t, 166-167  
 DPs (diffuse plaques), 104-105  
 Driving-related issues, 174-176  
 Drugs and drug therapies, 51-54, 113-152, 163-168  
   clinical courses *vs* treatment consequences, 115f  
   management strategies using, 163, 164t-165t, 166-168  
   overviews of, 113-114, 115f, 116, 117t  
   side effects of, 134  
   specific drugs and drug types. *See also under individual drugs and drug types.*  
      $\beta$ -blockers, 168  
     acetyl-L-carnitine, 147-149  
     ACh agonists, 117t  
     ACh precursors, 117t  
     ACh receptor blockers, 118-119  
     AChEs, 119, 120t, 121, 129, 130f, 131, 133-134  
     amitriptyline, 52t-53t  
     AN-1792, 147-149  
     antiarrhythmias, 54t  
     anticholinergic agents, 54t  
     anticonvulsants, 54t, 164t-165t, 168  
     antidepressants, 52t-54t, 164t-165t, 166-167  
     antihistamines, 54t  
     antihypertensive agents, 54t  
     anti-inflammatory agents, 116, 117t, 144-145  
     anti-luteinizing hormone therapies, 117t  
     antioxidants, 116, 117t, 139, 141-144  
     antipsychotics, 54t  
     anxiolytics, 164t-165t, 167  
     APP  $\beta$  and  $\gamma$  secretase inhibitors, 147-149  
     Aricept, 120t, 127, 128f, 129  
     aripiprazole, 164t  
     benzodiazepines, 164t-165t, 167  
     benzoquinone, 143-144  
     bupropion, 52t-53t  
     busiprone, 164t-165t, 167  
     butylcholinesterase, 119, 120t, 121  
     calcium antagonists, 147-149  
     carbamate inhibitors, 121  
     carbamazepine, 164t-165t, 168  
     celecoxib, 151t  
     cerebrolysin, 147-149  
     ChEIs, 114, 114f, 116, 117t, 118-119, 126-127, 131, 133-135, 136t, 139, 159  
     chelation therapy, 148-149  
     chlorpromazine, 163, 164t-165t, 166  
     cholinergic agonists, 118-119  
     cholinergic enhancements, 116, 117t, 118-119, 120t, 121, 122t-125t, 126-127, 128f, 129, 130f, 131, 132f, 133-135

citalopram, 52t-53t, 65t  
 clioquinol, 148-149  
 clonidine, 146-149  
 clozapine, 164t-165t, 166  
 Cognex, 126  
 conjugated equine estrogen, 150t-152t  
 CoQ, 117t, 143-144  
 corticosteroids, 54t  
 corticotropin-releasing factor enhancers, 117t  
 COX and COX-2 inhibitors, 117t, 144-145  
 Cymbalta, 52t-53t  
 decision tree for, 160f  
 deprenyl, 150t-152t  
 desipramine, 52t-53t, 165t  
 DHEA, 146  
 divalproex sodium, 164t  
 donepezil, 120t, 122t-123t, 127, 128f, 129, 139  
 dopamine agonists, 54t  
 doxepin, 52t-53t, 164t-165t, 166-167  
 duloxetine, 52t-53t  
 Effexor, 52t-53t  
 Eldepryl, 141  
 escitalopram, 52t-53t, 165t  
 estrogen, 117t, 146  
 Exelon, 120t, 129, 130f, 131  
 fluoxetine, 52t-53t, 165t  
 FPF 1070, 147-149  
 galantamine, 120t, 124t, 131, 132f, 133  
 ginkgo biloba, 143-144  
 glucocorticoids, 117t  
 glucose, 147-149  
 glutamate, 135, 137-139  
 growth factors, 117t  
 guanfacine, 146-149  
 haloperidol, 163, 164t-165t, 166  
 HMG CoA reductase inhibitors, 148-149  
 HRTs, 116, 117t, 145-146  
 Hup A, 133-134  
 idebenone, 143-144  
 ketamine, 137  
 lorazepam (short-acting), 164t-165t, 167  
 MAOIs, 141-144  
 medroxyprogesterone, 150t  
 melatonin, 168  
 memantine, 61, 117t, 124t, 135, 137-139, 140f  
 metrifonate, 133-134  
 mirtazapine, 52t-53t, 165t  
 MK-801, 137  
 monoamine oxidase type B inhibitors, 117t  
 mood stabilizers, 164t  
 muscle relaxants, 54t  
 Namenda, 138-139. *See also memantine.*  
 naproxen, 151t  
 narcotics, 54t

- neuroleptics (atypical), 164t-165t, 166  
neuroleptics (typical), 163, 164t-165t, 166  
neurotrophic agents, 147-149  
nicotine, 147-149  
nicotipine, 147-149  
NMDA receptor antagonists, 114, 114f, 116, 117t, 135, 137-139, 145-146  
nonadrenergic replacement therapies, 146-149  
nonspecific cholinesterases, 119, 120t, 121  
nonsteroidal anti-inflammatories, 117t, 144-145  
nootropics, 147-149  
Norpramin, 52t-53t  
nortriptyline, 52t-53t, 164t-165t, 166-167  
olanzapine, 164t-165t, 166  
opiate antagonists, 146-147  
overmedication and, 51, 52t-54t  
Pamelor, 52t-53t  
paroxetine, 52t-53t, 165t  
Paxil, 52t-53t  
PCP, 137  
pravastatin, 151t  
prednisone, 144-145  
progesterone, 146  
prolyl endopeptidase inhibitors, 117t  
propentofylline, 117t  
Prozac, 52t-53t  
quetiapine, 164t-165t, 166  
Reminyl, 120t, 131, 132f, 133  
risperidone, 164t-165t, 166  
rivastigmine, 120t, 122t-123t, 129, 130f, 131  
scopolamine, 118  
sedatives, 54t  
selegiline, 141-144, 142f  
selenium, 150t  
SERMs, 117t, 145-146  
serotonin agonists, 117t  
sertraline, 52t-53t, 164t-165t, 166-167  
simvastatin, 151t  
Sinequan, 52t-53t  
somatostatin replacement therapy with octreotide, 146-149  
SSRIs, 117t, 164t-165t, 166-167  
statins, 148-149  
tacrine, 121, 122t, 126-127  
thioridazine, 163, 164t-165t, 166  
thyrotropin-releasing hormone and analogues, 117t  
trazodone, 164t-165t, 166-167  
tricyclic antidepressants, 164t-165t, 166-167  
trifluoperazine, 163, 164t-165t, 166  
valproic acid, 164t-165t, 168  
venlafaxine, 52t-53t, 165t  
Wellbutrin, 52t-53t  
ziprasidone, 164t  
Zoloft, 52t-53t  
vitamin supplementation, 115t, 139, 140, 141-144, 142f  
overviews of, 139, 141-144  
vitamin C, 117t  
vitamin E (alpha-tocopherol), 115t, 117t, 141-144, 142t  
DSM IV (*Diagnostic and Statistical Manual of Mental Disorders*, fourth edition), 12-13  
Duloxetine, 52t-53t  
Early AD (Alzheimer's disease), 96-97  
Early diagnoses, 22t-23t  
Eating difficulties, 158-159  
Education and support (family), 169-182. *See also* Family education and support.  
Education (risk factor), 74-75  
EEGs (electroencephalograms), 41-42  
Effexor, 52t-53t, 165t  
Eldepryl, 141  
Elderweb, 185  
Electroencephalograms (EEGs), 41-42  
Embolisms (cerebral), 48t  
Emerging and current therapies, 113-152. *See also* Therapies (current and emerging).  
Encephalitis, 46t  
Endocrine and metabolic abnormalities, 46t, 54-55  
Enhancements (cholinergic). *See* Cholinergic enhancements.  
Epidemiology, 15-19  
etiologies, 17-18, 19f  
  clinic-based estimates, 19f  
  overviews of, 17-18  
  population-based estimates, 19f  
  incidence rates, 17  
  overviews of, 15  
  prevalence rates, 15, 16f, 17  
EPS (extrapyramidal symptoms), 91-92  
Escitalopram, 52t-53t, 165t  
Estrogen, 117t, 146  
Etiologies, 17-18, 19f  
  clinic-based estimates, 19f  
  population-based estimates, 19f  
Evaluation processes and procedures, 21-43. *See also* Assessments and evaluations.  
  algorithm for, 23, 24f  
  ancillary diagnostic studies, 37-43  
  brain biopsies, 43  
  for CJD, 41-42  
  CT, 38-40, 42-43  
  EEGs, 41-42  
  FDG-PET, 43  
  functional imaging studies and fMRI, 42-43, CP-1, CP-2  
  laboratory blood tests, 40-41  
  lumbar punctures and CSF analyses, 40-41  
  MRI, 38-43  
  neuropsychologic evaluations, 39  
  overviews of, 37-38  
  PET, 42-43

- polysomnography, 41-42
- structural imaging studies, 39-40
  - T1 and T2 scans, 40
  - VDRL tests, 38, 41
- common symptoms, 23t
- early diagnoses, 22t-23t
- measurement instruments for. *See* Measurement instruments.
- mental status assessments, 30-33, 34f, 35, 36t, 37
  - brief mental evaluations, 31-33
  - depression screenings, 35, 36, 37
  - MMSE and, 31-33, 34. *See also* MMSE (Mini-Mental State Examination).
  - overviews of, 30-31
- overviews of, 21-23, 22t-23t, 24f
- patient histories, 23, 25-27, 28f-29f
  - current symptoms and, 25-26
  - functional capabilities and, 25-26
  - medical histories and, 27, 28f-29f
  - neuropsychiatric histories and, 27, 28f-29f
  - overviews of, 23, 25
- physical examinations, 30

Exelon, 120t, 129, 130f, 131

Extrapyramidal symptoms (EPS), 91-92

FAD (familial Alzheimer's disease), 77, 78f, 80

Familial insomnia (fatal), 69-70

Family and clinician resources, 183-191

Family Caregiver Alliance, 185

Family education and support, 169-182

- assisted living options, 178, 179f, 180-181
- caregiving careers and caregiver stress, 170-171
- driving-related issues, 174-176
- financial and legal issues, 176-177
- hospice care, 182
- overviews of, 169-170
- physician-patient and physician-caregiver communication, 171-173
- residential care facilities, 178, 179f, 180-181
- respite care, 177-178
- safety issues, 174

Family histories (risk factor), 73

Fatal familial insomnia, 69-70

FDA (Food and Drug Administration), 121

FDG-PET (fluorodeoxyglucose-positron emission tomography), 43

Female gender (risk factor), 74

Financial and legal issues, 176-177

FLAIR (fluid-attenuated inversion recovery), 69-70

Fluorodeoxyglucose-positron emission tomography (FDG-PET), 43

Fluoxetine, 52t-53t, 165t

fMRIs, 42-43

Folate deficiency, 47t

Food and Drug Administration (FDA), 121

FPF 1070, 147-149

FTDs (frontotemporal dementias), 48t, 66-67, 68f, CP-1

Functional Assessment Questionnaire, 27, 28f-29f

Functional capabilities and patient histories, 25-26

Functional imaging studies and fMRI, 42-43, CP-1, CP-2

Fungal meningitis and encephalitis, 46t

Galantamine, 120t, 124t, 131, 132f, 133

GEMS (Ginkgo for the Evaluation of Memory), 150t-152t

Gender (risk factor), 74

Genetics, 76-77, 78f-79f, 80

- FAD (familial Alzheimer's disease), 77, 78f, 80
- known mutations and polymorphisms, 79f
- overviews of, 76-77, 78f-79f, 80
- pedigrees, 78f
- PS-1 and PS-2 (presenilin-1 and -2) genes, 77, 78f-79f, 80
- as risk factors, 73-74

Geodon, 164t

Geriatric Depression Scale, 35, 36t, 37

Gerstmann-Sträussler-Scheinker syndrome, 69-70

Ginkgo biloba, 143-144

Ginkgo for the Evaluation of Memory (GEMS), 150t-152t

Gliomas, 46t

Glucocorticoids, 117t

Glucose, 147-149

Glutamate, 135, 137-139

Growth factors, 117t

Guanfacine, 146-149

Hallervorden-Spatz disease, 48t

Hallucinations and delusions, 155-156

Haloperidol, 164t

Hamilton Depression Scale, 36f

HD (Huntington's disease), 48t, 71

Head injuries (risk factor), 75

Heart and Estrogen/Progestin Replacement Study (HERS), 150t-152t

Heart Protection Study, 150t-152t

Heavy metal toxicity, 46t

Hepatic failure, 46t, 54-55

HERS (Heart and Estrogen/Progestin Replacement Study), 150t-152t

Heterogeneity (clinical), 91-92

Histories (patient), 23, 25-27, 28f-29f

- current symptoms and, 25-26
- functional capabilities and, 25-26
- medical histories and, 27, 28f-29f

HIV (human immunodeficiency virus)-associated dementias, 71-72

HMG CoA reductase inhibitors, 148-149

Hospice care, 182

HRTs (hormone replacement therapies), 116, 117t, 145-146

Human immunodeficiency virus (HIV)-associated dementias, 71-72

Huntington's disease (HD), 48t, 71

Hup A (huperzine A), 133-134

Hydrocephalus (normal-pressure), 47t

Hyper- and hyponatremia, 46t

Hyper- and hypothyroidism, 46t, 54-55

- Hypercalcemia, 46t  
Hypoglycemia, 46t  
Hypopituitarism, 46t
- Idebenone, 143-144  
Incidence rates, 17  
Incidence trials and studies, 17  
Infections, 46t, 48t  
Inflammatory cascades, 106f  
Instruments (measurement). *See* Measurement instruments.  
Irreversible causes, 48t
- Ketamine, 137  
Khachaturian criteria, 110-111  
Known mutations and polymorphisms, 79f  
Kuf's disease, 48t  
Kuru, 69-70
- Laboratory blood tests, 40-41  
LBDs (Lewy body diseases), 48t, 62, 64, 65t, 92  
Legal and financial issues, 176-177  
Leukemia, 46t  
Lewy body diseases (LBDs), 48t, 62, 64, 65t, 92  
Lexapro, 52t-53t, 165t  
Ligands (diffusible), 104-105  
Lorazepam (short-acting), 164t-165t, 167  
Lumbar punctures and CSF (cerebrospinal fluid) analyses, 40-41  
Lupus erythematosus, 47t  
Lymphomas, 46t
- M1 (postsynaptic) and M2 (presynaptic) autoreceptors, 107-108  
MAC (membrane attack complex), 106f  
Magnetic resonance imaging (MRI), 38-43, 56-57, 59f, 69-70  
Management and diagnoses concepts. *See also under individual topics.*  
  AD-specific topics, 73-152  
    natural history, 89-99  
    pathophysiology and neuropathology, 101-111  
    risk factors, genetics, biomarkers, and diagnostic accuracy, 73-87  
    therapies (current and emerging), 113-152  
  clinical trials and studies. *See* Clinical trials and studies.  
  dementing disorders topics, 11-72  
    definitions, 11-13  
    epidemiology, 15-19  
    evaluation processes and procedures, 21-43  
    non-AD disorders, 45-72  
  drugs and drug therapies. *See* Drugs and drug therapies.  
  patient management topics, 153-182  
    agitation and behavioral symptom management, 153-168  
    family education and support, 169-182  
  resources and references for, 183-232  
    clinician and family resources, 183-191  
    references, 192-232
- Mania, 47t  
MAOIs (monamine oxidase inhibitors), 141-144
- MCI (mild cognitive impairment), 92-96, 153-154  
  agitation and behavior symptoms management and, 153-154  
  amnesic MCI, 94-96  
  non-amnesic MCI, 94-96  
  normal aging and, 92-94  
  subtypes diagnoses of, 95f
- Measurement instruments. *See also under individual instruments.*  
  ADAS-Cog, 121, 122t-125t, 126, 128f, 129, 130f, 132f, 134-135  
  ADCS-ADL Inventory, 132f  
  ADCS-ADLsev Inventory, 140f  
  CIBIC-Plus, 121, 122t-125t, 126, 128f, 129, 130f, 134-135, 140f  
  Cornell Scale for Depression in Dementia, 36f  
  Demential Mood Assessment, 36f  
  Functional Assessment Questionnaire, 27, 28f-29f  
  Geriatric Depression Scale, 35, 36t, 37  
  Hamilton Depression Scale, 36f  
  MMSE, 11-12, 31-33, 34f, 35-36, 90-91, 91f, 126, 127, 128f, 129, 131, 133, 151t, 172, 175-176, 179f  
  NPI, 132f  
  PDS, 130f  
  QoL Scale, 128f, 129  
  SIB, 140f  
  TICSm, 150t-152t
- Medical histories, 27, 28f-29f. *See also* Patient histories.  
Medroxyprogesterone, 150t  
Melatonin, 168  
Memantine, 61, 117t, 124t, 135, 137-139, 140f  
Membrane attack complex (MAC), 106f  
Meningiomas, 46t  
Meningitis and encephalitis, 46t  
Mental inactivity (risk factor), 76  
Mental status assessments, 30-33, 34f, 35, 36t, 37  
  brief mental evaluations, 31-33  
  depression screenings, 35, 36, 37  
  MMSE and, 31-33, 34. *See also* MMSE (Mini-Mental State Examination).  
  overviews of, 30-31
- Metabolic and endocrine abnormalities, 46t, 54-55  
Metachromatic leukodystrophy, 48t  
Metastatic tumors, 46t  
Metrifonate, 133-134  
MIDs (multi-infarct dementias), 56-57  
Mild AD (Alzheimer's disease), 96-97  
Mini-Mental State Examination (MMSE), 11-12, 31-33, 34f, 35-36, 90-91, 91f, 126-127, 128f, 129, 131, 133, 172, 175-176, 179f  
MIRAGE (Multi-Institutional Research in Alzheimer's Genetic Epidemiology) Study, iv  
Mirtazapine, 52t-53t, 165t  
Mixed dementias, 55-57, 58t, 59f, 60-61  
MK-801, 137  
MMSE (Mini-Mental State Examination), 11-12, 31-33, 34f, 35-36, 90-91, 91f, 126-127, 128f, 129, 131, 133, 172, 175-176, 179f  
Moderate AD (Alzheimer's disease), 97-98



- Modified Telephone Interview for the Cognitive Status questionnaire (TICSM), 150t-152t
- Monamine oxidase inhibitors (MAOIs), 141-144
- Monoamine oxidase type B inhibitors, 117t
- Mood stabilizers, 164t
- MRI (magnetic resonance imaging), 38-43, 56-57, 59f, 69-70
- MS (multiple sclerosis), 47t-48t
- Multi-Institutional Research in Alzheimer's Genetic Epidemiology (MIRAGE) Study, iv
- Multiple sclerosis (MS), 47t-48t
- Muscle relaxants, 54t
- Mutations and polymorphisms, 79f
- Myoclonus, 92
- Named trials and studies. *See* Clinical trials and studies.
- Namenda, 138-139. *See also* memantine.
- Naproxen, 151t
- Narcotics, 54t
- National Academy of Elder Law Attorneys, 184
- National Association of Area Agencies on Aging, 185
- National Council on Aging, 185
- National Hospice and Palliative Care Organization, 185
- National Institute on Aging, 86-87, 186
- National Library of Medicine, 184-186
- Natural history, 89-99
  - advanced AD, 98-99
    - clinical heterogeneity, 91-92
    - early (mild) AD, 96-97
  - EPS, 91-92
  - MCI, 92-96
    - amnesic MCI, 94-96
    - non-amnesic MCI, 94-96
    - normal aging and, 92-94
    - overviews of, 94
    - subtypes diagnoses of, 95f
  - moderate AD, 97-98
  - overviews of, 89
  - progression rates, 89-91, 90f
- Neoplasms, 46t
- Neuritic plaques (NPs), 104-105
- Neuroleptics, 163, 164t-165t, 166
  - atypical, 164t-165t, 166
  - typical, 163, 164t-165t, 166
- Neuronal death, 101-102, 103f, 104, 105f
- Neuropathic changes, 104-105, 111
- Neuropathology and pathophysiology, 101-111
  - animal models, 111
  - neuropathic changes, 104-105, 111
    - ADDLs, 104-105
    - APOE and, 111
    - A $\beta$  peptides, 101-102, 103f, 104, 105f
    - DPs, 104-105
    - neuronal death, 101-102, 103f, 104, 105f
    - NFTs, 101-102, 103f, 104, 105f
    - NPs, 104-105
    - SPs and blood vessels, 101-102, 103f, 104, 105f
  - neuropathologic diagnoses criteria, 108-111
    - CERAD and, 110-111
    - M1 (postsynaptic) and M2 (presynaptic) autoreceptors and, 107-108
    - NIA-NINCDS (Khachaturian) criteria and, 110-111
    - overviews of, 108-111
  - neurotransmitter system abnormalities, 105-108, 106f-107f
    - AChs and, 106-108
    - ChATs and, 106-108, 107f
    - cholinergic synapses, 107f
    - inflammatory cascades, 106f
    - MAC and, 106f
    - overviews of, 105-108
    - overviews of, 101
  - Neurophycholegic evaluations, 39
  - Neuropsychiatric histories, 27, 28f-29f. *See also* Patient histories.
  - Neuropsychiatric Inventory (NPI), 132f
  - Neurosyphilis, 46t
  - Neurotransmitter system abnormalities, 105-108, 106f-107f
  - Neurotrophic agents, 147-149
  - NFTs (neurofibrillary tangles), 101-102, 103f, 104, 105f
  - NIA-NINCDS (Khachaturian) criteria, 110-111
  - Nicotine, 147-149
  - NIH (National Institutes of Health), 144-145, 184, 186
  - Nimodipine, 147-149
  - NINCDS-ADRDA criteria, 84t-85t
  - NINDS-AIREN criteria, 57, 57t, 60-61
  - NMDA (*N*-methyl-D-aspartate) receptor antagonists, 114, 114f, 116, 117t, 135, 137-139, 145-146
- Non-AD (Alzheimer's disease) disorders, 45-72
  - autoimmune disorders, 47t
  - CAA and, 60-61
  - CADASIL and, 60-61
  - degenerative diseases, 48t
  - depression, 47t, 49, 50t, 51
  - DLBDs, 48t, 62, 64, 65t
  - FTDs, 48t, 66-67, 68f, CP-1
  - HD, 48t, 71
  - HIV-associated dementias, 71-72
  - infections, 46t, 48t
  - irreversible causes of, 48t
  - LBDs, 48t, 62, 64, 65t
  - metabolic and endocrine abnormalities, 46t, 54-55
  - MiDs, 56-57
  - mixed dementias, 55-57, 58t, 59f, 60-61
  - neoplasms, 46t
  - NINDS-AIREN criteria for, 57, 57t, 60-61
  - nutritional disorders, 47t
  - overmedication, 47t, 51, 52t-54t
  - overviews of, 45, 46t-48t, 49
  - PD and Parkinsonian syndromes, 48t, 61-62, 63t
  - potentially reversible causes of, 46t-48t
  - prion diseases, 69-70

psychiatric disorders, 47t  
 toxins, 46t  
 trauma, 46t  
 VaDs, 48t, 55-57, 58t, 59f, 60-61  
 Nondrergic replacement therapies, 146-149  
 Non-amnesic MCI (mild cognitive impairment), 94-96  
 Nonpharmacologic management strategies, 161, 162t  
 Nonspecific cholinesterases, 119, 120t, 121  
 Nonsteroidal anti-inflammatories, 117t, 144-145  
 Nootropics, 147-149  
 Normal aging, 92-94  
 Normal-pressure hydrocephalus, 47t  
 Norpramin, 52t-53t, 165t  
 Nortriptyline, 52t-53t, 164t-165t, 166-167  
 NPI (Neuropsychiatric Inventory), 132f  
 NPs (neuritic plaques), 104-105  
 Nutritional disorders, 47t  
  
 Octreotide, 146-149  
 Olanzapine, 164t-165t, 166  
 Olivopontocerebellar atrophy and degeneration, 48t, 63t  
 Onset delay treatments, 149, 150t-152t  
 Opiate antagonists, 146-147  
 Organic poisons, 46t  
 Outcomes (measurement instruments). *See* Measurement instruments.  
 Overmedication, 47t, 51, 52t-54t  
 Overviews. *See also under individual topics.*  
   of AD, 73-74, 89, 101, 113-114  
     natural history, 89  
     pathophysiology and neuropathology, 101  
     risk factors, genetics, biomarkers, and diagnostic accuracy, 73-74  
     therapies (current and emerging), 113-114  
   of dementing disorders, 11, 15, 21-24, 45-49  
     definitions, 11  
     epidemiology, 15  
     evaluation processes and procedures, 21-23, 22t-23t, 24f  
     non-AD (Alzheimer's disease) disorders, 45, 46t-48t, 49  
   of patient management topics, 153-154, 169-170  
     agitation and behavioral symptoms management, 153-154  
     family education and support, 169-170  
  
 Pacing and wandering, 156-157  
 Pamelor, 52t-53t, 165t  
 Parasitic meningitis and encephalitis, 46t  
 Parkinson's disease (PD) and Parkinsonian syndromes, 48t, 61-62, 63t  
 Paroxetine, 52t-53t, 165t  
 Pathophysiology and neuropathology, 101-111  
   animal models, 111  
   neuropathic changes, 104-105, 111  
     ADDLs, 104-105  
     APOE, 111  
     A $\beta$  peptides, 101-102, 103f, 104, 105f  
     DPs, 104-105  
     neuronal death, 101-102, 103f, 104, 105f  
     NFTs, 101-102, 103f, 104, 105f  
     NPs, 104-105  
     SPs and blood vessels, 101-102, 103f, 104, 105f  
   neuropathologic diagnoses criteria, 108-111  
     CERAD and, 110-111  
     M1 and M2 autoreceptors and, 107-108  
     NIA-NINCDS (Khachaturian) criteria and, 110-111  
     overviews of, 108-111  
   neurotransmitter system abnormalities, 105-108, 106f-107f  
     AChs and, 106-108  
     ChATs and, 106-108, 107f  
     cholinergic synapses, 107f  
     inflammatory cascades, 106f  
     MAC and, 106f  
     overviews of, 105-108  
     overviews of, 101  
   Patient histories, 23, 25-27, 28f-29f  
     current symptoms and, 25-26  
     functional capabilities and, 25-26  
     medical histories and, 27, 28f-29f  
     neuropsychiatric histories and, 27, 28f-29f  
   Patient management topics, 153-182. *See also under individual topics.*  
     agitation and behavioral symptom management, 153-168  
     family education and support, 169-182  
   Paxil, 52t-53t, 165t  
   PCP, 137  
   PD (Parkinson's disease) and Parkinsonian syndromes, 48t, 61-62, 63t  
   PDS (Progressive Deterioration Scale), 130f  
   Pedigrees, 78f  
   Pellagra, 47t  
   Peptides (A $\beta$ ), 101-102, 103f, 104, 105f, 147-149  
   Pernicious anemia, 47t  
   PET (positron emission tomography), 42-43  
   Pharmacologic therapies. *See* Drugs and drug therapies.  
   Physical activity (risk factor), 76  
   Physical and verbal agitation, 154-155  
   Physical examinations, 30  
   Physician-patient and physician-caregiver communication, 171-173  
   Pick's disease, 67-69  
   Plaques, 101-105  
     DPs, 104-105  
     NPs, 104-105  
     SPs and blood vessels, 101-102, 103f, 104, 105f  
   Poisons (organic), 46t  
   Polymorphisms and mutations, 79f  
   Polysomnography, 41-42  
   Population-based estimates, 19f  
   Positron emission tomography (PET), 42-43  
   Postencephalitic dementias, 48t  
   Postsynaptic (M1) and presynaptic (M2) autoreceptors, 107-108  
   Potentially reversible causes, 46t-48t  
   Pravastatin, 151t  
   PREADVISE (Prevention of Alzheimer's Disease by Vitamin E and Selenium), 150t-152t

- Prednisone, 144-145
- Presenilin-1 and -2 (PS-1 and PS-2) genes, 77, 78f-79f, 80
- Presynaptic (M2) autoreceptors, 107-108
- Prevalence rates, 15, 16f, 17
- Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE), 150t-152t
- Preventive and onset delay treatments, 149, 150t-152t
- Primary AIDS encephalopathy, 46t
- Prion diseases, 69-70
- Progesterone, 146
- Progression rates, 89-91, 90f
- Progressive Deterioration Scale (PDS), 130f
- Progressive multifocal leukoencephalopathy, 48t
- Progressive supranuclear failure, 63t
- Progressive supranuclear palsy, 48t
- Prolyl endopeptidase inhibitors, 117t
- Propentofylline, 117t
- Prospective (cohort) trials and studies, 15
- PROSPER, 151t-152t
- Protective factors, 75-76
- Prozac, 52t-53t, 165t
- PS-1 and PS-2 (presenilin-1 and -2) genes, 77, 78f-79f, 80
- Psychiatric disorders, 47t
- Psycho-behavioral metaphors, 154
- Psychoses, 47t
- QoL (Quality of Life) Scale, 128f, 129
- Quetiapine, 164t-165t, 166
- Readings. *See* Resources and references.
- Reference resources, 183-192
- Remeron, 52t-53t, 165t
- Reminyl, 120t, 131, 132f, 133
- Renal failure, 46t, 54-55
- Research studies and trials. *See* Clinical trials and studies.
- Resources and references, 183-232
  - clinician and family resources, 183-191
  - references, 192-232
- Retrospective (case-control) trials and studies, 15
- REVEAL (Risk Evaluation and Education in Alzheimer's) Study, iv, 81
- Reversible causes, 46t-48t
- Risk factors, genetics, biomarkers, and diagnostic accuracy, 73-87
  - APOE, 80-81
  - biomarkers, 81
  - diagnostic accuracy, 82-83, 84t-85t, 86-87
    - NINCDS-ADRDA criteria and, 84t-85t
    - overviews of, 82-87
  - genetics, 76-77, 78f-79f, 80
    - FAD, 77, 78f, 80
    - known mutations and polymorphisms, 79f
    - overviews of, 76-77, 78f-79f, 80
    - pedigrees, 78f
    - PS-1 and PS-2 genes, 77, 78f-79f, 80
  - overviews of, 73-74
  - risk factors, 73-75, 74f
    - age, 73
    - education, 74-75
    - family histories, 73
    - female gender, 74
    - genetic factors, 73-74, 74f
    - head injuries, 75
    - mental inactivity, 76
    - overviews of, 73
    - physical activity, 76
    - vs protective factors, 75-76
    - vascular disease, 75
    - vitamin supplementation, 76
- Risperdal, 164t
- Risperidone, 164t, 166
- Rivastigmine, 120t, 122t-123t, 129, 130f, 131
- Sarcoidosis, 47t
- Schizophrenia, 47t
- Scopolamine, 118
- Secretase inhibitors ( $\beta$  and  $\gamma$ ), 147-149
- Sedatives, 54t
- Selective estrogen receptor modulators (SERMs), 117t, 145-146
- Selective serotonin reuptake inhibitors (SSRIs), 117t, 164t-165t, 166-167
- Selegiline, 141-144, 142f
- Selenium, 150t
- SERMs (selective estrogen receptor modulators), 117t, 145-146
- Seroquel, 164t
- Serotonergic antidepressants, 165t
- Serotonin agonists, 117t
- Sertraline, 52t-53t, 164t-165t, 166-167
- Serum acidosis or alkalosis, 54-55
- Shy-Drager syndrome, 63t
- SIB (Severe Impairment Battery), 140f
- Simvastatin, 151t
- Sinequan, 52t-53t
- Sleep apnea, 47t
- Sleep disruption, 158
- Social Security Administration, 186
- Somatostatin replacement therapy with octreotide, 146-149
- Specific AD (Alzheimer's disease) topics, 73-152. *See also under individual topics.*
  - natural history, 89-99
  - pathophysiology and neuropathology, 101-111
    - risk factors, genetics, biomarkers, and diagnostic accuracy, 73-87
    - therapies (current and emerging), 113-152
- SPs (senile plaques) and blood vessels, 101-102, 103f, 104, 105f
- SSRIs (selective serotonin reuptake inhibitors), 117t, 164t-165t, 166-167
- Statins, 148-149
- Stress (caregiver), 170-171
- Striatonigral degeneration, 63t
- Structural imaging studies, 39-40
- Studies and trials. *See* Clinical trials and studies.
- Subacute spongiform encephalopathy. *See* CJD (Creutzfeldt-Jakob disease).

Subdural hematomas (acute and chronic), 46t  
 Subprogressive multifocal leukoencephalopathy, 48t  
 Subtypes diagnoses, 95f  
 Support and education (family), 169-182. *See also* Family education and support.  
 Symptoms (common), 23t  
  
 T1 and T2 scans, 40  
 Tacrine (tetrahydroaminoacridine), 121, 122t, 126-127  
 Tegretol, 164t  
 Telephone Interview for the Cognitive Status questionnaire modified (TICSm), 150t-152t  
 Temporal arteritis, 47t  
 Tetrahydroaminoacridine, 121, 122t, 126-127  
 Therapies (current and emerging), 113-152  
   emerging therapies, 146-149  
   management strategies, 113-114  
   overviews of, 113-114  
   pharmacologic therapies, 114-152. *See also* Drugs and drug therapies.  
     anti-inflammatory therapies, 144-145  
     antioxidant therapies, 139, 140f, 141-144, 142f  
     cholinergic enhancement, 118-119, 120t, 121, 122t-125t, 126-127, 128f, 129, 130f, 131, 132f, 133-134  
     diet, 139, 140f, 141-144, 142f  
     hormone therapies, 145-146  
     NMDA receptor antagonism, 135, 136t, 137-139  
     overviews of, 114, 115f, 116, 117t  
     vitamin supplementation, 139, 140f, 141-144, 142f  
   preventive and onset delay treatments, 149, 150t-152t  
 Thiamine deficiency, 47t  
 Thioridazine, 163, 164t-165t, 166  
 Thyroid diseases, 46t  
 Thyrotropin-releasing hormone and analogues, 117t  
 TICSm (modified Telephone Interview for the Cognitive Status questionnaire), 150t-152t  
 Toxins, 46t  
 Trauma, 46t  
 Trazodone, 164t-165t, 166-167  
 Treatment consequences vs clinical courses, 115f  
 Trials and studies. *See* Clinical trials and studies.  
 Tricyclic antidepressants, 164t-165t, 166-167  
 Trifluoperazine, 163, 164t-165t, 166  
 Typical neuroleptics, 163, 164t-165t, 166  
  
 Unsuccessful aging shorthand definition, 11-12  
  
 VaDs (vascular dementias), 48t, 55-57, 58t, 59f, 60-61  
 Valproic acid, 164t-165t, 168  
 Vascular dementias (VaDs), 48t, 55-57, 58t, 59f, 60-61  
 Vascular disease (risk factor), 75  
 Vasculitis, 47t  
 VDRL (Venereal Disease Research Laboratory) tests, 38, 41  
 Venlafaxine, 52t-53t  
 Verbal and physical agitation, 154-155  
  
 Viral meningitis and encephalitis, 46t  
 Vitamin supplementation, 47t, 76, 115t, 139, 140, 141-144, 142f  
   overviews of, 139, 141-144  
   as protective factors, 76  
   vitamin B<sub>6</sub> deficiency, 47t  
   vitamin B<sub>12</sub> deficiency, 47t  
   vitamin C, 117t  
   vitamin E (alpha-tocopherol), 115t, 117t, 141-144, 142t  
  
 Wandering and pacing, 156-157  
 Wellbutrin, 52t-53t  
 Wernicke-Korsakoff syndrome, 47t  
 Wernicke's encephalopathy, 47t  
 WHI-PERT (Women's Health Initiative-Progestin and Estrogen Replacement Therapy) study, 146, 151t-152t  
 Whipple's disease, 47t  
 Wilson's disease, 46t, 48t  
 Women's Health Initiative-Progestin and Estrogen Replacement Therapy (WHI-PERT) study, 146, 151t-152t  
  
 Ziprasidone, 164t  
 Zolof, 52t-53t, 165t  
 Zyprexa, 164t